This refresh
Data-driven refresh July 29, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,229 tickers); 1,481 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. DOCS — Doximity, Inc. · score 90.7
Health Information Services · price $21.63 · 1Y $24.61 · 5Y $36.03 · 10Y $53.45
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 22.1x B+ · PEG 0.59 A-
Why now. DOCS’s AI‑driven workflow tool Ask is cementing the platform as the go‑to clinical knowledge hub for U.S. physicians, fueling a 13.1% revenue growth rate and a 30.4% profit margin that translates into a ROE of 20.6%. Those fundamentals underpin our Bull Rankings model’s 90.7 quality‑growth score, with Growth as the strongest pillar, and justify the consensus 1‑yr target of $24.61. The thesis rests on the compounding power of the AI assistant expanding its user base while margins stay high.
Moat. The platform’s network of over 80% of U.S. physicians creates a lock‑in effect: clinicians rely on Ask for HIPAA‑compliant evidence retrieval, making migration costly and time‑consuming. This sticky user base fuels premium ad pricing from pharma and health systems, driving the high ROE and sustaining the growth pillar of our model.
Risk. A 3% implied FCF growth from the reverse‑DCF is far below the 13.1% revenue growth, suggesting the market is already pricing in aggressive optimism; combined with a lofty P/E of 22.1 and a beta of 1.29, any slowdown in user adoption or a shift to rival AI platforms could compress multiples and trigger a sell‑off. A breach of the 52‑week low ($17.15) would confirm the bear case.
Horizon. 1-3 yr $24.61 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $36.03 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $53.45 if current growth sustains into durable earnings power.
2. ADBE — Adobe Inc. · score 89.1
Software - Application · price $263.43 · 1Y $269.61 · 5Y $394.73 · 10Y $585.56
FCF $10.3b A- · Rev +11.5% B · D/E 0.61 C+ · P/E 15.1x A- · PEG 0.65 A-
Why now. Adobe’s Digital Experience platform is the engine behind the company’s 11.5% YoY revenue growth, and its 28.7% profit margin fuels a 62.8% ROE that our model rates 92/100 in Quality. The platform’s integration of analytics, commerce and content creation locks in marketers, agencies and publishers, creating a high switching‑cost ecosystem that keeps revenue recurring and margins stable. The current price already prices in only 1%/yr free‑cash‑flow growth over 10 years, far below the 11.5% revenue expansion, so the upside is clear.
Moat. The Digital Experience segment’s unified platform gives Adobe a network effect: each new marketer or agency that adopts Adobe Analytics, Target and Commerce automatically pulls in more customers for its Creative Cloud suite. This cross‑sell power, combined with the company’s 62.8% ROE driven by pricing power in the enterprise content‑creation market, creates a moat that competitors cannot replicate quickly.
Risk. Adobe’s beta of 1.43 and a P/E of 15.1 suggest the market is already rewarding growth, yet the 0.65 PEG indicates the price may be over‑optimistic relative to earnings growth. A slowdown in the digital‑marketing spend cycle or a shift to open‑source design tools could erode the Digital Experience moat, and a rise in debt‑to‑equity beyond 0.61 would pressure cash flow and buyback capacity.
Horizon. 1-3 yr $269.61 (analyst consensus (n=34)) — fundamentals + valuation re-rating. 5 yr $394.73 at ~8% CAGR — compounding case rests on the competitive position widening. 10 yr $585.56 if current growth sustains into durable earnings power.
3. DLO — DLocal Limited · score 89
Software - Infrastructure · price $14.59 · 1Y $18.05 · 5Y $26.43 · 10Y $39.20
FCF $413m C · Rev +46.6% A · D/E 0.20 B+ · P/E 22.8x B+ · PEG 0.49 A
Why now. DLocal’s pay‑in platform for cross‑border e‑commerce, streaming and ride‑hailing merchants is exploding, delivering 46.6% YoY revenue growth while preserving an 18% profit margin and generating $413 m of free cash flow. Those fundamentals sit under our model’s strongest pillar – Growth (100) – and the 34.6% ROE shows the business can reinvest at high returns, meaning the compounding engine will keep running as emerging‑market digital payments expand. The thesis hinges on sustaining this high‑growth payment moat.
Moat. The moat lives in DLocal’s end‑to‑end payment stack – from global card and alternative‑payment‑method acceptance to the dLocal for Platforms suite – which locks in merchants that need a single partner for cross‑border and local‑to‑local payouts. This integration creates switching costs and pricing power, reflected in a 34.6% ROE, far above sector averages, and a low debt‑to‑equity of 0.2 that lets the firm invest aggressively without balance‑sheet strain.
Risk. The bear case centers on the reverse DCF, which implies a -6% annual free‑cash‑flow growth over the next decade – a stark contrast to the 46.6% revenue surge, suggesting the current $14.59 price already embeds unrealistic optimism. Coupled with shareholder dilution flagged by our model, any slowdown in merchant adoption or margin compression would push the 22.8× PE into overvaluation territory and invalidate the growth premium.
Horizon. 1-3 yr $18.05 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $26.43 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $39.20 if current growth sustains into durable earnings power.
4. INTU — Intuit Inc. · score 87.9
Software - Application · price $333.13 · 1Y $456.47 · 5Y $668.32 · 10Y $991.41
FCF $7.8b B+ · Rev +15.1% B+ · D/E 0.33 B · P/E 20.3x B+ · PEG 0.79 A-
Why now. Intuit’s QuickBooks ecosystem, now bolstered by Mailchimp’s marketing automation, is driving a 15.1% YoY revenue growth while delivering a 21.9% profit margin and a 22.2% ROE, feeding a virtuous compounding loop of higher‑margin SaaS subscriptions and financing fees. Our Bull Rankings model rates INTU at a Quality‑Growth score of 87.9, with Growth as the strongest pillar, confirming that the business’s cash‑generating engine is the key catalyst. The thesis rests on the continued expansion of the SMB customer base that increasingly bundles QuickBooks, payroll, and Mailchimp, sustaining the high‑growth trajectory.
Moat. The moat lives in the end‑to‑end financial workflow Intuit provides to small‑ and mid‑market businesses—QuickBooks accounting, payroll, merchant processing, and financing—all tied to a single data hub that makes switching costly. This lock‑in, combined with a 22%+ ROE generated from pricing power in a category‑lead position, creates a durable cash‑flow advantage that competitors can’t replicate quickly.
Risk. The market is pricing INTU for aggressive growth: a forward P/E of 20.3 and a reverse‑DCF implying a -2% annual free‑cash‑flow growth over ten years, far below the reported 15.1% revenue expansion, signaling that any slowdown would trigger a sharp re‑rating. The model’s weakest pillar, Value, flags that the current valuation leaves little margin for error; a miss on the next‑quarter revenue or margin would validate the bear view and collapse the upside.
Horizon. 1-3 yr $456.47 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $668.32 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $991.41 if current growth sustains into durable earnings power.
5. NBIX — Neurocrine Biosciences, Inc. · score 87.4
Drug Manufacturers - Specialty & Generic · price $180.79 · 1Y $202.17 · 5Y $296.00 · 10Y $439.10
FCF $831m C+ · Rev +28.6% A- · D/E 0.14 B+ · P/E 27.8x B · PEG 0.50 A
Why now. INGREZZA is the compounding engine: 28.6% revenue growth in FY YoY and $831M in TTM free cash flow prove the franchise is still accelerating. The company’s shift from endocrine to neurology assets—CRENESSITY for congenital adrenal hyperplasia and NBI-1076986 for movement disorders—means the growth is diversifying beyond tardive dyskinesia. The PEG of 0.5 says the multiple is cheap for the growth rate, and our model’s 87.4 Quality-growth score (Growth pillar at 100) confirms the setup. The crux: can INGREZZA’s dominance in tardive dyskinesia hold as competitors like Teva and AbbVie advance their chorea pipelines?
Moat. INGREZZA’s moat is built on the first-mover advantage in VMAT2 inhibition for tardive dyskinesia: neurologists default to the only FDA-approved drug in the class, creating a switching cost measured in patient inertia and formulary lock-in. The 21.6% profit margin and 19.6% ROE aren’t just high—they’re sustained by pricing power in a niche with no generics and limited substitutes, a durability our model’s Quality pillar (82) captures. Competitors would need to clear the same FDA hurdles and physician education curve, which takes years.
Risk. The bear case is that INGREZZA’s tardive dyskinesia monopoly erodes as Teva’s deutetrabenazine (Austedo) gains traction in chorea and AbbVie’s ABBV-951 enters the market by 2028. The P/E of 27.8 assumes INGREZZA’s growth persists, but if market share slips, the multiple contracts fast. The concrete signal to break the bull thesis: INGREZZA’s revenue growth decelerates below 15% while the rest of the pipeline fails to offset the loss.
Horizon. 1-3 yr $202.17 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $296.00 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $439.10 if current growth sustains into durable earnings power.
6. NVDA — NVIDIA Corporation · score 86.6
Semiconductors · price $190.01 · 1Y $302.83 · 5Y $443.37 · 10Y $657.71
FCF $119.1b A · Rev +70.7% A · D/E 0.07 A- · P/E 29.1x B · PEG 0.54 A-
Why now. NVIDIA’s Compute & Networking segment is cementing its role as the backbone of AI data‑center infrastructure, and that engine is exploding – revenue is up 70.7% YoY, free‑cash‑flow hits a massive $119.1 B, and profit margins sit at a staggering 63%. Our Bull Rankings model awards NVDA an 86.6/100 quality‑growth score, with Growth as the strongest pillar, underscoring a business that compounds at break‑neck speed. The reverse‑DCF shows today’s price implies only ~46% annual FCF growth for the next decade, well below the 70% revenue surge, meaning the market is still under‑pricing the compounding power of its AI‑centric platform. The thesis rests on continued AI‑driven data‑center demand fueling relentless cash generation.
Moat. NVDA’s moat lives in its AI‑accelerated computing stack – from GeForce GPUs to the data‑center accelerators that power the world’s largest AI models – creating massive switching costs for hyperscale cloud providers and enterprise customers. The 81.7% ROE reflects pricing power derived from being the de‑facto standard in high‑performance compute, a position rivals can’t replicate without years of silicon R&D and ecosystem lock‑in.
Risk. The stock trades at a lofty PE of 29.1 and a beta of 2.21, exposing investors to valuation compression if AI spend cools or macro volatility spikes. Our model flags Value as the weakest pillar, warning that the current premium may be unsustainable if revenue growth decelerates from the current 70.7% pace. A sustained slowdown or a sharp pull‑back in data‑center spend would push the price toward the 52‑week low of $164.07, confirming the bear case.
Horizon. 1-3 yr $302.83 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $443.37 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $657.71 if current growth sustains into durable earnings power.
7. HRMY — Harmony Biosciences Holdings, Inc. · score 85.1
Biotechnology · price $35.86 · 1Y $45.40 · 5Y $66.47 · 10Y $98.60
FCF $342m C · Rev +20.7% A- · D/E 0.18 B+ · P/E 14.5x A- · PEG 0.67 A-
Why now. Harmony’s commercial‑stage narcolepsy drug WAKIX anchors a high‑margin franchise (16.2% profit margin) while the pipeline of Phase‑2/3 pitolisant indications fuels a 20.7% YoY revenue growth trajectory; the stock trades at a modest PE of 14.5x and a sub‑1 PEG (0.67), meaning the market already rewards earnings growth but still leaves upside as each new indication adds recurring cash. The thesis rests on the compounding of WAKIX cash flow plus incremental sales from Prader‑Willi and Myotonic Dystrophy approvals, which should keep earnings expanding at double‑digit rates for years.
Moat. WAKIX’s novel histamine‑H3 antagonism gives Harmony a protected position in the rare‑neurology niche, where insurers and specialists lock patients into a single, FDA‑approved therapy, creating high switching costs. The company’s 16% ROE reflects pricing power derived from this exclusivity and the ability to command premium pricing in a market with few alternatives, reinforcing a durable cash‑flow moat.
Risk. The Bull Rankings model’s reverse‑DCF implies a -19% annual free‑cash‑flow growth rate, an optimism gap that assumes the company can sustain cash‑flow expansion far beyond its 20.7% revenue growth; any delay or failure in the Phase‑2/3 pitolisant trials would collapse that premium, leaving the stock over‑valued at a PE of 14.5x for a biotech still reliant on a single commercial product. A miss on the pipeline would confirm the bear case and force the price back toward its 52‑week low.
Horizon. 1-3 yr $45.40 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $66.47 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $98.60 if current growth sustains into durable earnings power.
8. ADMA — ADMA Biologics, Inc. · score 85
Biotechnology · price $8.71 · 1Y $17.00 · 5Y $24.89 · 10Y $36.92
FCF $108m C · Rev +11.0% B · D/E 1.11 C · P/E 12.8x A · PEG 0.65 A-
Why now. ADMA is a compounding machine disguised as a $2B biotech: its 42.4% ROE and 32.4% profit margin prove it can turn plasma-derived biologics into cash at industrial scale, while 11% revenue growth is the steady drumbeat of demand for IVIG in primary humoral immunodeficiency. The crux? ASCENIV and BIVIGAM are the only FDA-approved IVIGs manufactured in the U.S., locking in pricing power and supply-chain security that no offshore competitor can replicate quickly.
Moat. The moat is built on two pillars: first, domestic plasma-derived biologics manufacturing — ADMA’s ADMA BioManufacturing segment controls the only U.S.-based IVIG production lines for ASCENIV and BIVIGAM, creating a 12-18 month regulatory lead time for any rival trying to replicate capacity. Second, plasma collection centers feed the biologics pipeline with controlled, high-quality plasma, reducing input cost volatility and ensuring consistent yields that competitors sourcing from third-party plasma brokers cannot match.
Risk. The bear case is simple: debt-to-equity of 1.11 is high for a growth biotech, and if ASCENIV’s pricing erodes under payer pressure or BIVIGAM’s market share slips to biosimilar IVIGs, the 12.8x P/E will look rich. The concrete signal to sell? A sustained decline in U.S. IVIG ASP below $100/g or a competitor gaining FDA approval for a domestic IVIG line before 2028.
Horizon. 1-3 yr $17.00 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $24.89 at ~23% CAGR — compounding case rests on the competitive position widening. 10 yr $36.92 if current growth sustains into durable earnings power.
9. TTD — The Trade Desk, Inc. · score 85
Advertising Agencies · price $19.09 · 1Y $24.32 · 5Y $35.61 · 10Y $52.82
FCF $842m C+ · Rev +15.5% B+ · D/E 0.17 A- · P/E 21.7x B · PEG 0.85 B+
Why now. The Trade Desk’s unrivaled CTV and video‑first platform is fueling a 15.5% FY revenue growth while delivering a 14.6% profit margin and generating $842 m of free cash flow—a trifecta that validates our model’s top‑scoring Growth pillar (93). At a PEG of 0.85 the market is pricing modest upside, but the real engine is the compounding ad‑tech moat that will keep cash‑flows expanding, making the 1‑yr consensus target of $24.32 a near‑term catalyst for the next growth wave.
Moat. TTD’s unified buying platform spans CTV, video, display, audio and native formats, locking in agencies and advertisers who rely on its data‑rich, cross‑device optimization—switching costs are high because campaigns are built on proprietary APIs and audience insights. This stickiness underpins a 17.6% ROE, driven by pricing power in a market where every impression is programmatically bought through TTD’s technology.
Risk. The stock trades at a 21.7× forward P/E, far above the sector average, and our reverse‑DCF shows the current price assumes a -4% annual free‑cash‑flow decline for a decade—an optimism gap given the 15.5% revenue growth may decelerate. A slowdown in CTV spend or a shift to rival platforms would push the valuation below the implied growth, and a breach of the 52‑week low $16.70 would confirm the bear case.
Horizon. 1-3 yr $24.32 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $35.61 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $52.82 if current growth sustains into durable earnings power.
10. EXLS — ExlService Holdings, Inc. · score 84.1
Information Technology Services · price $35.99 · 1Y $40.13 · 5Y $58.75 · 10Y $87.15
FCF $297m C · Rev +13.4% B+ · D/E 0.67 C+ · P/E 22.9x B+ · PEG 0.91 B+
Why now. EXLS is compounding its way into the AI services oligopoly by turning actuarial and risk analytics from the Insurance segment into a subscription-like revenue stream, and the numbers prove it: 13.4% revenue growth, 32.3% ROE, and $297M in trailing free cash flow show a business that is both growing and capital-efficient. Our model’s Growth pillar at 91/100 confirms this is the strongest lever in the stack, and the crux is simple — EXLS is selling AI-driven policy servicing and underwriting support to insurers who can’t afford to build it themselves.
Moat. The moat is the data flywheel inside the Insurance and Healthcare & Life Sciences segments, where EXLS embeds actuarial models into claims management and premium administration workflows; once a client’s data is in the system, switching costs rise because the models learn from that client’s historical claims and underwriting patterns. The 32.3% ROE isn’t generic pricing power — it’s the result of reusing actuarial IP across multiple insurers while keeping marginal costs flat, a feat that would take a competitor years to replicate even with a full salesforce.
Risk. The bear case is that EXLS is a premium-multiple growth name trading at a 22.9x P/E while the Insurance segment’s growth is tied to a single macro cycle — if claims inflation accelerates or premiums compress, the analytics tailwind turns into a cost center for clients and growth stalls. The concrete signal to watch is a deceleration in Insurance segment revenue growth below 10% for two consecutive quarters; that would break the bull thesis because the model’s Value pillar at 77/100 already flags that the multiple is pricing in durability that isn’t guaranteed.
Horizon. 1-3 yr $40.13 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $58.75 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $87.15 if current growth sustains into durable earnings power.
11. CARG — CarGurus, Inc. · score 83.3
Auto & Truck Dealerships · price $37.07 · 1Y $37.77 · 5Y $55.30 · 10Y $82.03
FCF $293m C · Rev +14.0% B+ · D/E 0.79 B · P/E 19.5x B · PEG 1.06 B+
Why now. Auto & Truck Dealerships · market cap $3.3b. 6% off the 52-week high of $39.42. Revenue growing +14%, comfortably above the S&P median. 13 sell-side analysts rate this a Buy with a mean 1-yr target of $37.77 (implying +2% upside).
Moat. Net margin 16% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 63% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 196% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $37.77 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $55.30 at ~8% CAGR — compounding case rests on the competitive position widening. 10 yr $82.03 if current growth sustains into durable earnings power.
12. RMD — ResMed Inc. · score 83
Medical Instruments & Supplies · price $214.29 · 1Y $248.60 · 5Y $363.98 · 10Y $539.93
FCF $1.8b C+ · Rev +10.3% B · D/E 0.13 B+ · P/E 20.7x B+ · PEG 1.21 B
Why now. Medical Instruments & Supplies · market cap $31.1b. Down 27% from 52-week high of $293.81 — deep drawdown territory. Revenue growing +10%, comfortably above the S&P median. 15 sell-side analysts rate this a Buy with a mean 1-yr target of $248.60 (implying +16% upside).
Moat. Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $248.60 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $363.98 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $539.93 if current growth sustains into durable earnings power.
13. EPAM — EPAM Systems, Inc. · score 82.6
Information Technology Services · price $106.89 · 1Y $135.24 · 5Y $170.73 · 10Y $218.96
FCF $544m C+ · Rev +14.2% B+ · D/E 0.08 B+ · P/E 15.4x A- · PEG 0.49 A
Why now. Information Technology Services · market cap $5.6b. Down 52% from 52-week high of $222.53 — deep drawdown territory. Revenue growing +14%, comfortably above the S&P median. PEG 0.49 — paying under fair value for the growth rate. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $135.24 (implying +27% upside).
Moat. ROE 11% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 141% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 52% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.43 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $135.24 (analyst consensus (n=17)) — multiple re-rating thesis requires a catalyst. 5 yr $170.73 at ~10% CAGR — dividend + buyback compounding. 10 yr $218.96 if the moat survives secular pressure.
14. VEEV — Veeva Systems Inc. · score 81.9
Health Information Services · price $207.91 · 1Y $244.14 · 5Y $357.45 · 10Y $530.25
FCF $1.7b C+ · Rev +16.2% B+ · D/E 0.01 A- · P/E 36.9x C+ · PEG 0.88 B+
Why now. Health Information Services · market cap $33.8b. Down 33% from 52-week high of $310.50 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. PEG 0.88 — paying under fair value for the growth rate. 28 sell-side analysts rate this a Buy with a mean 1-yr target of $244.14 (implying +17% upside).
Moat. Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 177% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 33% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 37x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 10.2x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
Horizon. 1-3 yr $244.14 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $357.45 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $530.25 if current growth sustains into durable earnings power.
15. IT — Gartner, Inc. · score 81.8
Information Technology Services · price $165.65 · 1Y $160.38 · 5Y $202.48 · 10Y $259.68
FCF $1.3b C+ · Rev +2.3% C · D/E n/a · P/E 16.4x A- · PEG 0.64 A-
Why now. Information Technology Services · market cap $11.1b. Down 53% from 52-week high of $352.08 — deep drawdown territory. PEG 0.64 — paying under fair value for the growth rate. 13 sell-side analysts rate this a Hold with a mean 1-yr target of $160.38 (implying -3% upside).
Moat. FCF converts 170% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 53% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $160.38 (analyst consensus (n=13)) — multiple re-rating thesis requires a catalyst. 5 yr $202.48 at ~4% CAGR — dividend + buyback compounding. 10 yr $259.68 if the moat survives secular pressure.
16. DXCM — DexCom, Inc. · score 81.6
Medical Devices · price $75.14 · 1Y $86.16 · 5Y $126.15 · 10Y $187.13
FCF $1.4b C+ · Rev +16.1% B+ · D/E 0.47 B · P/E 32.2x B · PEG 1.37 B
Why now. Medical Devices · market cap $29.0b. 16% off the 52-week high of $89.98. Revenue growing +16%, comfortably above the S&P median. 25 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $86.16 (implying +15% upside).
Moat. Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 31% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 154% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Beta 1.45 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 32x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $86.16 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $126.15 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $187.13 if current growth sustains into durable earnings power.
17. PRDO — Perdoceo Education Corporation · score 81.3
Education & Training Services · price $34.55 · 1Y $37.31 · 5Y $47.11 · 10Y $60.41
FCF $225m C · Rev +17.7% B+ · D/E 0.12 A- · P/E 13.2x A- · PEG 0.68 A-
Why now. Education & Training Services · market cap $2.2b. 10% off the 52-week high of $38.50. Revenue growing +18%, comfortably above the S&P median. PEG 0.68 — paying under fair value for the growth rate.
Moat. Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 132% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $37.31 (structural (no analyst coverage)) — multiple re-rating thesis requires a catalyst. 5 yr $47.11 at ~6% CAGR — dividend + buyback compounding. 10 yr $60.41 if the moat survives secular pressure.
18. YELP — Yelp Inc. · score 80.4
Internet Content & Information · price $27.92 · 1Y $26.71 · 5Y $33.73 · 10Y $43.25
FCF $281m C · Rev +2.1% C · D/E 0.25 A- · P/E 12.8x A- · PEG 0.57 A-
Why now. Internet Content & Information · market cap $1.5b. Down 21% from 52-week high of $35.26 — deep drawdown territory. PEG 0.57 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Hold with a mean 1-yr target of $26.71 (implying -4% upside).
Moat. ROE 22% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $26.71 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $33.73 at ~4% CAGR — dividend + buyback compounding. 10 yr $43.25 if the moat survives secular pressure.
19. APP — AppLovin Corporation · score 80.3
Advertising Agencies · price $399.46 · 1Y $654.60 · 5Y $958.40 · 10Y $1,422
FCF $4.4b B · Rev +66.4% A · D/E 1.63 C · P/E 34.7x C+ · PEG 1.13 B+
Why now. Advertising Agencies · market cap $134.2b. Down 46% from 52-week high of $745.61 — deep drawdown territory. Revenue growing +66% — in hypergrowth territory. 30 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $654.60 (implying +64% upside).
Moat. Net margin 64% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. FCF converts 112% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. $134.2b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Down 46% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 2.48 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 35x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $654.60 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $958.40 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $1,422 if current growth sustains into durable earnings power.
20. META — Meta Platforms, Inc. · score 80.3
Internet Content & Information · price $585.61 · 1Y $824.68 · 5Y $1,041 · 10Y $1,335
FCF $48.3b A · Rev +26.2% A- · D/E 0.36 B+ · P/E 21.3x B · PEG 0.87 B+
Why now. Internet Content & Information · market cap $1.5T. Down 26% from 52-week high of $796.25 — deep drawdown territory. Revenue growing +26% — in hypergrowth territory. PEG 0.87 — paying under fair value for the growth rate. 57 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $824.68 (implying +41% upside).
Moat. Net margin 33% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 29% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $1.5T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $824.68 (analyst consensus (n=57)) — multiple re-rating thesis requires a catalyst. 5 yr $1,041 at ~12% CAGR — dividend + buyback compounding. 10 yr $1,335 if the moat survives secular pressure.
21. MELI — MercadoLibre, Inc. · score 79.5
Internet Retail · price $1863.31 · 1Y $2,215 · 5Y $3,243 · 10Y $4,810
FCF $11.8b A- · Rev +36.4% A · D/E 1.70 C+ · P/E 49.3x D · PEG 1.12 B+
Why now. Internet Retail · market cap $94.5b. Down 27% from 52-week high of $2548.50 — deep drawdown territory. Revenue growing +36% — in hypergrowth territory. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $2,215 (implying +19% upside).
Moat. ROE 26% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. $94.5b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Trailing P/E 49x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. E-commerce competition — Amazon, Walmart, Shein, and Temu have each forced the rest of the category to compete on price, fulfillment speed, or assortment; sustaining margins requires one of those being structurally defended.
Horizon. 1-3 yr $2,215 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,243 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $4,810 if current growth sustains into durable earnings power.
22. DECK — Deckers Outdoor Corporation · score 79.2
Footwear & Accessories · price $103.54 · 1Y $122.81 · 5Y $155.04 · 10Y $198.84
FCF $1.1b C+ · Rev +9.8% B · D/E 0.21 A- · P/E 14.7x A- · PEG 1.21 B
Why now. Footwear & Accessories · market cap $14.1b. 17% off the 52-week high of $125.45. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $122.81 (implying +19% upside).
Moat. Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 107% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $122.81 (analyst consensus (n=21)) — multiple re-rating thesis requires a catalyst. 5 yr $155.04 at ~8% CAGR — dividend + buyback compounding. 10 yr $198.84 if the moat survives secular pressure.
23. PODD — Insulet Corporation · score 79
Medical Devices · price $170.62 · 1Y $235.54 · 5Y $344.86 · 10Y $511.57
FCF $416m C · Rev +31.9% A · D/E 0.78 C+ · P/E 40.0x C+ · PEG 1.46 B
Why now. Medical Devices · market cap $11.8b. Down 52% from 52-week high of $354.88 — deep drawdown territory. Revenue growing +32% — in hypergrowth territory. 24 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $235.54 (implying +38% upside).
Moat. ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 137% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 52% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 40x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $235.54 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $344.86 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $511.57 if current growth sustains into durable earnings power.
24. FIVE — Five Below, Inc. · score 77.9
Specialty Retail · price $209.49 · 1Y $260.48 · 5Y $328.85 · 10Y $421.74
FCF $505m C+ · Rev +25.9% A- · D/E 0.86 B · P/E 26.5x C+ · PEG 0.98 B+
Why now. Specialty Retail · market cap $11.6b. 17% off the 52-week high of $251.63. Revenue growing +26% — in hypergrowth territory. PEG 0.98 — paying under fair value for the growth rate. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $260.48 (implying +24% upside).
Moat. ROE 19% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $260.48 (analyst consensus (n=21)) — multiple re-rating thesis requires a catalyst. 5 yr $328.85 at ~9% CAGR — dividend + buyback compounding. 10 yr $421.74 if the moat survives secular pressure.
25. CRDO — Credo Technology Group Holding Ltd · score 77.7
Semiconductors · price $177.45 · 1Y $279.29 · 5Y $408.90 · 10Y $606.58
FCF $407m C · Rev +205.7% A · D/E 0.01 A · P/E 70.4x C · PEG 0.34 A
Why now. Semiconductors · market cap $33.1b. Down 43% from 52-week high of $308.67 — deep drawdown territory. Revenue growing +206% — in hypergrowth territory. PEG 0.34 — paying under fair value for the growth rate. 19 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $279.29 (implying +57% upside).
Moat. Net margin 35% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Semiconductor moat is process-design IP plus customer qualification timelines — once designed in, the company captures multiple product cycles before a competitor can displace.
Risk. Trailing P/E 70.4x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Down 43% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 3.20 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $279.29 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $408.90 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $606.58 if current growth sustains into durable earnings power.
26. VRT — Vertiv Holdings Co · score 77.4
Electrical Equipment & Parts · price $223.04 · 1Y $376.15 · 5Y $550.73 · 10Y $816.97
FCF $2.9b B · Rev +26.2% A- · D/E 0.77 B · P/E 55.9x C · PEG 1.35 B
Why now. Electrical Equipment & Parts · market cap $85.7b. Down 41% from 52-week high of $379.94 — deep drawdown territory. Revenue growing +26% — in hypergrowth territory. 26 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $376.15 (implying +69% upside).
Moat. Net margin 15% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 36% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 169% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Trailing P/E 55.9x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Down 41% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 2.03 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $376.15 (analyst consensus (n=26)) — fundamentals + valuation re-rating. 5 yr $550.73 at ~20% CAGR — compounding case rests on the competitive position widening. 10 yr $816.97 if current growth sustains into durable earnings power.
27. EME — EMCOR Group, Inc. · score 77.1
Engineering & Construction · price $672.48 · 1Y $991.57 · 5Y $1,252 · 10Y $1,605
FCF $1.1b C+ · Rev +18.3% B+ · D/E 0.13 A- · P/E 22.6x B+ · PEG 0.40 A
Why now. Engineering & Construction · market cap $29.9b. Down 29% from 52-week high of $951.96 — deep drawdown territory. Revenue growing +18%, comfortably above the S&P median. PEG 0.40 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $991.57 (implying +47% upside).
Moat. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $991.57 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $1,252 at ~13% CAGR — dividend + buyback compounding. 10 yr $1,605 if the moat survives secular pressure.
28. NFLX — Netflix, Inc. · score 75.9
Entertainment · price $73.63 · 1Y $94.33 · 5Y $138.10 · 10Y $204.87
FCF $11.2b A- · Rev +16.0% B+ · D/E 0.55 B · P/E 23.2x B · PEG 1.58 C+
Why now. Entertainment · market cap $306.6b. Down 42% from 52-week high of $126.71 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. 45 sell-side analysts rate this a Buy with a mean 1-yr target of $94.33 (implying +28% upside).
Moat. Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 45% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $306.6b market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Down 42% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.52 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $94.33 (analyst consensus (n=45)) — fundamentals + valuation re-rating. 5 yr $138.10 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $204.87 if current growth sustains into durable earnings power.
29. FISV — Fiserv, Inc. · score 75.2
Sector n/a · price $55.63 · 1Y $66.63 · 5Y $84.12 · 10Y $107.88
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 9.4x A- · PEG 2.62 C
Why now. Sector n/a · market cap $29.7b. Down 61% from 52-week high of $142.83 — deep drawdown territory. 27 sell-side analysts rate this a Hold with a mean 1-yr target of $66.63 (implying +20% upside).
Moat. Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 129% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 61% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $66.63 (analyst consensus (n=27)) — multiple re-rating thesis requires a catalyst. 5 yr $84.12 at ~9% CAGR — dividend + buyback compounding. 10 yr $107.88 if the moat survives secular pressure.
30. ULTA — Ulta Beauty, Inc. · score 75
Specialty Retail · price $508.09 · 1Y $623.42 · 5Y $912.74 · 10Y $1,354
FCF $1.1b C+ · Rev +11.3% B · D/E 0.89 B · P/E 19.0x B+ · PEG 1.67 C+
Why now. Specialty Retail · market cap $21.8b. Down 29% from 52-week high of $714.97 — deep drawdown territory. Revenue growing +11%, comfortably above the S&P median. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $623.42 (implying +23% upside).
Moat. ROE 46% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 95% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $623.42 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $912.74 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $1,354 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.